BPC‑157 and KPV Peptides — Informed Consent (Research Peptides / Investigational Use)

INFORMED CONSENT FOR BPC‑157 AND KPV PEPTIDES — RESEARCH/INVESTIGATIONAL USE

§1 PURPOSE, CONTEXT, AND SCOPE

§1.1 This document constitutes an informed consent agreement between the Patient identified herein (the "Patient") and the Prescribing Physician acting on behalf of the Clinic. It is intended to document that the Patient has received, understood, and accepted comprehensive information regarding the proposed use of BPC‑157 and/or KPV, which are research/investigational peptides.

§1.2 CRITICAL NOTICE — RESEARCH PEPTIDES: BPC‑157 and KPV are research peptides that have NOT been approved by any regulatory agency (EMA, FDA, or equivalent) for any clinical indication. They are investigational compounds. By proceeding with this consent, the Patient acknowledges the experimental and unregulated nature of this treatment.

§1.4 Health optimization context: The Patient understands that the Clinic operates as a proactive health optimization / longevity practice. The Clinic is not an emergency provider.

§1.5 This consent is governed by the laws of Denmark and the European Union, including but not limited to the Danish Health Act (Sundhedsloven) and Regulation (EU) 2016/679 (General Data Protection Regulation).

§1.6 By signing this document, the Patient confirms they have had adequate time to read, consider, and ask questions.

§3 COMPOUND DESCRIPTIONS AND REGULATORY STATUS

§3.1 BPC‑157 (Body Protective Compound‑157):

§3.1.1 BPC‑157 is a synthetic peptide consisting of 15 amino acids, derived from a portion of a protein found in human gastric juice. It has been studied primarily in preclinical (cell and animal) models for its potential effects on tissue healing and protection.

§3.1.2 Preclinical research suggests BPC‑157 may have effects on:

  • Gut mucosal healing and protection
  • Tendon, ligament, and muscle healing
  • Angiogenesis (blood vessel formation)
  • Nitric oxide pathways
  • Neurotrophic effects

§3.1.3 REGULATORY STATUS — NOT APPROVED:

  • BPC‑157 is NOT approved by the EMA, FDA, or any regulatory authority for any indication
  • No completed human clinical trials have established safety or efficacy
  • Use in humans is based on animal research and anecdotal reports only

§3.2 KPV (Lysine‑Proline‑Valine):

§3.2.1 KPV is a tripeptide (3 amino acids) derived from alpha‑melanocyte‑stimulating hormone (α‑MSH). It has been studied primarily in preclinical models for its potential anti‑inflammatory properties.

§3.2.2 Preclinical research suggests KPV may have effects on:

  • Modulation of inflammatory pathways
  • Antimicrobial properties
  • Gut inflammation
  • Wound healing

§3.2.3 REGULATORY STATUS — NOT APPROVED:

  • KPV is NOT approved by the EMA, FDA, or any regulatory authority for any indication
  • No human clinical trials have established safety or efficacy
  • Use in humans is based on preclinical research and anecdotal reports only

§3.4 Manufacturing and quality: The Patient understands that:

  • These peptides are obtained from research chemical suppliers or compounding facilities
  • Quality, purity, and consistency may vary
  • Manufacturing standards may not meet pharmaceutical (GMP) requirements
  • The Patient accepts the risk of product variability and potential contaminants

§4 INTENDED USE AND RATIONALE

§4.1 Intended use in this Clinic: BPC‑157 and/or KPV are being used as part of a health optimization protocol, with the hypothesis that they may support:

  • Gut healing and integrity
  • Tissue repair and recovery
  • Modulation of inflammation
  • General healing processes

§4.2 Critical limitations: The Patient understands that:

  • Evidence is from cell and animal studies only
  • Translation to humans is uncertain
  • No human clinical trials have established efficacy or optimal dosing
  • Benefits in humans are entirely hypothetical

§5 PROPOSED BENEFITS (NO GUARANTEE — HYPOTHETICAL)

§5.1 Based on preclinical research and anecdotal reports, proposed potential benefits may include:

  • Improved gut healing (ulcers, inflammatory bowel conditions)
  • Enhanced tissue healing (tendons, muscles, injuries)
  • Reduced inflammation
  • Improved recovery from injury or surgery

§5.2 CRITICAL DISCLAIMER: The Patient understands that:

  • These proposed benefits are entirely hypothetical in humans
  • No human clinical trials have demonstrated these effects
  • Many patients may experience no benefit
  • Benefits are not guaranteed
  • The Patient is using these compounds with full knowledge that they are experimental

§6 MATERIAL RISKS AND ADVERSE EFFECTS

§6.1 LIMITED SAFETY DATA: Long‑term safety data in humans does not exist.

§6.2 Known or anticipated adverse effects (BPC‑157):

  • Injection site reactions (pain, redness, swelling)
  • Nausea or gastrointestinal discomfort
  • Dizziness
  • Hot flashes
  • Headache

§6.3 Known or anticipated adverse effects (KPV):

  • Injection site reactions
  • Nausea
  • Headache
  • Fatigue

§6.4 Unknown risks: The Patient understands that:

  • Long‑term effects are completely unknown
  • Effects on cancer risk are unknown (angiogenic peptides like BPC‑157 could theoretically promote tumor vascularization — this is unstudied)
  • Effects on cardiovascular, immune, and other systems are unknown
  • Drug interactions are unstudied
  • Rare or serious adverse effects may exist but have not been identified

§6.5 Theoretical concerns regarding BPC‑157:

  • As BPC‑157 may promote angiogenesis, there is theoretical concern about potential effects on tumor growth or progression in individuals with undiagnosed cancer. This has not been studied.
  • The Patient should disclose any history of cancer or suspicious symptoms.

§6.6 Product quality risks: Due to the unregulated nature of research peptides:

  • Contamination is possible
  • Degradation during storage or shipping is possible
  • Sterility cannot be guaranteed to pharmaceutical standards

§7 CONTRAINDICATIONS AND PRECAUTIONS

§7.1 Due to lack of safety data, the following are general precautions:

  • Active malignancy or history of cancer (theoretical concern regarding angiogenesis for BPC‑157)
  • Known allergy or prior reaction to these peptides
  • Active severe infection
  • Children and adolescents (not studied)

§7.2 The Patient confirms they have disclosed all relevant medical history.

§8 DRUG AND SUPPLEMENT INTERACTIONS

§8.1 Drug interactions are unstudied. The Patient agrees to inform the Clinic of all medications and supplements and to report any unusual symptoms.

§9 ADMINISTRATION AND DOSING

§9.1 BPC‑157 and KPV are typically administered by subcutaneous injection. Oral formulations of BPC‑157 may also be available.

§9.2 Dosing: Optimal dosing in humans is unknown. Dosing is based on preclinical data extrapolation and anecdotal experience.

§9.3 The Patient will be instructed on proper technique, storage, and disposal.

§9.4 Storage: These peptides typically require refrigeration.

§10 MONITORING

§10.1 No established monitoring protocol exists. The Patient agrees to report any adverse effects promptly.

§11 ALTERNATIVE TREATMENTS

§11.1 Alternatives include:

  • Evidence‑based treatments for specific conditions (e.g., PPIs for ulcers, anti‑inflammatories for injuries)
  • Lifestyle interventions
  • No treatment with research peptides

§11.2 The Patient has chosen to proceed with research peptides.

§13 LIMITATION OF LIABILITY / NO GUARANTEE

§13.1 The Patient understands that BPC‑157 and KPV are research compounds with no regulatory approval.

§13.2 Benefits are entirely hypothetical and not guaranteed. Long‑term safety is unknown.

§13.3 The Patient accepts responsibility for the decision to use unapproved research compounds.

§13.4 Nothing in this consent excludes liability that cannot be excluded under applicable Danish law.

§14 WITHDRAWAL OF CONSENT

§14.1 The Patient may withdraw consent and discontinue use at any time.

§15 DATA PROTECTION

§15.1 The Patient's personal data will be processed in accordance with GDPR.

§16 ACKNOWLEDGMENTS AND DECLARATIONS

By consenting, the Patient confirms the following:

  • I have read this consent document in its entirety and understand its contents.
  • I understand that BPC‑157 and KPV are RESEARCH PEPTIDES with NO REGULATORY APPROVAL.
  • I understand that NO HUMAN CLINICAL TRIALS have established safety or efficacy.
  • I understand that all proposed benefits are HYPOTHETICAL.
  • I understand that LONG‑TERM SAFETY DATA DOES NOT EXIST.
  • I understand the theoretical concern about angiogenesis and cancer (for BPC‑157).
  • I understand the risks of product contamination or variability.
  • I accept the experimental nature of this treatment.
  • I have disclosed all relevant medical history and current medications.
  • I understand I must seek emergency care for severe symptoms.
  • I have had the opportunity to ask questions.
  • I voluntarily consent to use the prescribed medication understanding its research/investigational status.